The effects of the IRA on our business and the healthcare industry in general is not yet known.
All entries for: Metabolic Diseases
March 10, 2026
Esperion Therapeutics, Inc.
Neutral Outlook
Ann Arbor, MI
201-500 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Cardiology, Gastrointestinal, Metabolic Diseases
Drug Type: Small Molecule
March 9, 2026
Zevra Therapeutics
Neutral Outlook
Boston, MA
51-200 employees
On August 16, 2022, the Inflation Reduction Act (“IRA”), of 2022, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and the list of the subsequent 15 drugs that will be subject to negotiation, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.
Disease Area: Cardiology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
March 9, 2026
Editas Medicine
Neutral Outlook
Cambridge, MA
201-500 employees
On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years
Disease Area: Cardiology, Hematology, Immune Diseases, Metabolic Diseases, Oncology, Rare Diseases
Drug Type: Biologic
March 9, 2026
Septerna Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Metabolic Diseases
Drug Type: Small Molecule
March 9, 2026
Corbus Pharmaceuticals Holding, Inc
Negative Outlook
Norwood, MA
51-200 employees
Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain…For example, the Inflation Reduction Act of 2022 included, among other things, a provision that authorizes CMS to negotiate a “maximum fair price” for a limited number of high-cost, single-source drugs every year, and another provision that requires drug companies to pay rebates to Medicare if prices rise faster than inflation.
Disease Area: Metabolic Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 5, 2026
GSK plc
Negative Outlook
London, England
10,000+ employees
In ovarian cancer, Zejula saw a decrease in sales, driven by ongoing volume reductions, including impacts of an FDA labelling update restricting use to certain patient populations, and the impacts of IRA Medicare Part D redesign in the US
Disease Area: Antiviral, Chronic Disease, Gastrointestinal, Hematology, Immune Diseases, Infectious Diseases, Metabolic Diseases, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
March 5, 2026
Lexicon Pharmaceuticals
Negative Outlook
The Woodlands, TX
51-200 employees
Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time.
Disease Area: Cardiology, Endocrinology, Metabolic Diseases, Neurological Diseases
Drug Type: Small Molecule